Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Adults with a BMI of 27.0 or greater with 2 or more related complications or a BMI of 35.0 or greater with 1 or more related complications were enrolled.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Running at several centres spread the Semaglutide study over different clinics and patient groups.

The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea.

Data were analyzed from March 2022 to July 2025.

What Was Measured

PubMed files the paper under topics including Body Mass Index, Diabetes Mellitus, Type 2, East Asian People, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Hypoglycemic Agents and Japan.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (JAMA internal medicine), a journal based in United States.

More context: the Semaglutide compound page, all human trials.